These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 16300476)

  • 61. Quaternary substituted PDE4 inhibitors I: the synthesis and in vitro evaluation of a novel series of oxindoles.
    Hulme C; Poli GB; Huang FC; Souness JE; Djuric SW
    Bioorg Med Chem Lett; 1998 Jan; 8(2):175-8. PubMed ID: 9871649
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Dynamic activation of cystic fibrosis transmembrane conductance regulator by type 3 and type 4D phosphodiesterase inhibitors.
    Liu S; Veilleux A; Zhang L; Young A; Kwok E; Laliberté F; Chung C; Tota MR; Dubé D; Friesen RW; Huang Z
    J Pharmacol Exp Ther; 2005 Aug; 314(2):846-54. PubMed ID: 15901792
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Preferential inhibition of T helper 1, but not T helper 2, cytokines in vitro by L-826,141 [4-[2-(3,4-Bisdifluromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]3-methylpyridine-1-oxide], a potent and selective phosphodiesterase 4 inhibitor.
    Claveau D; Chen SL; O'Keefe S; Zaller DM; Styhler A; Liu S; Huang Z; Nicholson DW; Mancini JA
    J Pharmacol Exp Ther; 2004 Aug; 310(2):752-60. PubMed ID: 15082748
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Identification of substrate specificity determinants in human cAMP-specific phosphodiesterase 4A by single-point mutagenesis.
    Richter W; Unciuleac L; Hermsdorf T; Kronbach T; Dettmer D
    Cell Signal; 2001 Mar; 13(3):159-67. PubMed ID: 11282454
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Identification of inhibitor specificity determinants in a mammalian phosphodiesterase.
    Atienza JM; Susanto D; Huang C; McCarty AS; Colicelli J
    J Biol Chem; 1999 Feb; 274(8):4839-47. PubMed ID: 9988724
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Comparison of recombinant human PDE4 isoforms: interaction with substrate and inhibitors.
    Saldou N; Obernolte R; Huber A; Baecker PA; Wilhelm R; Alvarez R; Li B; Xia L; Callan O; Su C; Jarnagin K; Shelton ER
    Cell Signal; 1998 Jun; 10(6):427-40. PubMed ID: 9720765
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The synthesis and biological evaluation of a novel series of phthalazine PDE4 inhibitors I.
    Napoletano M; Norcini G; Pellacini F; Marchini F; Morazzoni G; Ferlenga P; Pradella L
    Bioorg Med Chem Lett; 2000 Oct; 10(19):2235-8. PubMed ID: 11012037
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A new chemical tool for exploring the role of the PDE4D isozyme in leukocyte function.
    Chambers RJ; Abrams K; Castleberry TA; Cheng JB; Fisher DA; Kamath AV; Marfat A; Nettleton DO; Pillar JD; Salter ED; Sheils AL; Shirley JT; Turner CR; Umland JP; Lam KT
    Bioorg Med Chem Lett; 2006 Feb; 16(3):718-21. PubMed ID: 16263279
    [TBL] [Abstract][Full Text] [Related]  

  • 69. CoMFA and CoMSIA 3D-quantitative structure-activity relationship model on benzodiazepine derivatives, inhibitors of phosphodiesterase IV.
    Ducrot P; Andrianjara CR; Wrigglesworth R
    J Comput Aided Mol Des; 2001 Sep; 15(9):767-85. PubMed ID: 11776290
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Splice variants of the cyclic nucleotide phosphodiesterase PDE4D are differentially expressed and regulated in rat tissue.
    Richter W; Jin SL; Conti M
    Biochem J; 2005 Jun; 388(Pt 3):803-11. PubMed ID: 15717866
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Involvement of type 4 cAMP-phosphodiesterase in the myogenic differentiation of L6 cells.
    Naro F; Sette C; Vicini E; De Arcangelis V; Grange M; Conti M; Lagarde M; Molinaro M; Adamo S; Némoz G
    Mol Biol Cell; 1999 Dec; 10(12):4355-67. PubMed ID: 10588663
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Assessing the emetic potential of PDE4 inhibitors in rats.
    Robichaud A; Savoie C; Stamatiou PB; Lachance N; Jolicoeur P; Rasori R; Chan CC
    Br J Pharmacol; 2002 Jan; 135(1):113-8. PubMed ID: 11786486
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Cyclic nucleotide phosphodiesterase 3B is a downstream target of protein kinase B and may be involved in regulation of effects of protein kinase B on thymidine incorporation in FDCP2 cells.
    Ahmad F; Cong LN; Stenson Holst L; Wang LM; Rahn Landstrom T; Pierce JH; Quon MJ; Degerman E; Manganiello VC
    J Immunol; 2000 May; 164(9):4678-88. PubMed ID: 10779773
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Inhibition of platelet-derived growth factor-induced mitogenesis by phosphodiesterase 3 inhibitors: role of protein kinase A in vascular smooth muscle cell mitogenesis.
    Osinski MT; Schrör K
    Biochem Pharmacol; 2000 Aug; 60(3):381-7. PubMed ID: 10856433
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Crystal structures of the catalytic domain of phosphodiesterase 4B complexed with AMP, 8-Br-AMP, and rolipram.
    Xu RX; Rocque WJ; Lambert MH; Vanderwall DE; Luther MA; Nolte RT
    J Mol Biol; 2004 Mar; 337(2):355-65. PubMed ID: 15003452
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Synthesis and structure-activity relationship of N-arylrolipram derivatives as inhibitors of PDE4 isozymes.
    Keller TH; Bray-French K; Demnitz FW; Müller T; Pombo-Villar E; Walker C
    Chem Pharm Bull (Tokyo); 2001 Aug; 49(8):1009-17. PubMed ID: 11515569
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6, 7,1-hi]indoles: discovery of potent, selective phosphodiesterase type 4 inhibitors.
    Burnouf C; Auclair E; Avenel N; Bertin B; Bigot C; Calvet A; Chan K; Durand C; Fasquelle V; Féru F; Gilbertsen R; Jacobelli H; Kebsi A; Lallier E; Maignel J; Martin B; Milano S; Ouagued M; Pascal Y; Pruniaux MP; Puaud J; Rocher MN; Terrasse C; Wrigglesworth R; Doherty AM
    J Med Chem; 2000 Dec; 43(25):4850-67. PubMed ID: 11123995
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Cyclic-3',5'-nucleotide phosphodiesterase isozymes in cell biology and pathophysiology of the kidney.
    Dousa TP
    Kidney Int; 1999 Jan; 55(1):29-62. PubMed ID: 9893113
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Synergistic inhibition of vascular smooth muscle cell migration by phosphodiesterase 3 and phosphodiesterase 4 inhibitors.
    Palmer D; Tsoi K; Maurice DH
    Circ Res; 1998 May; 82(8):852-61. PubMed ID: 9576105
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Aryl sulfonamides as selective PDE4 inhibitors.
    Montana JG; Buckley GM; Cooper N; Dyke HJ; Gowers L; Gregory JP; Hellewell PG; Kendall HJ; Lowe C; Maxey R; Miotla J; Naylor RJ; Runcie KA; Tuladhar B; Warneck JB
    Bioorg Med Chem Lett; 1998 Oct; 8(19):2635-40. PubMed ID: 9873594
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.